Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V.

Clin Cancer Res. 2019 Jun 7. pii: clincanres.2860.2018. doi: 10.1158/1078-0432.CCR-18-2860. [Epub ahead of print]

PMID:
31175096
2.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 May 15. pii: S2213-2600(19)30139-0. doi: 10.1016/S2213-2600(19)30139-0. [Epub ahead of print]

PMID:
31103412
3.

Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.

Hann CL, Scherpereel A, Hellyer JA, Wakelee HA.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:543-552. doi: 10.1200/EDBK_237847. Epub 2019 May 17.

PMID:
31099677
4.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
5.

Use of Immune Checkpoint Inhibitors in Mesothelioma.

Forde PM, Scherpereel A, Tsao AS.

Curr Treat Options Oncol. 2019 Feb 14;20(2):18. doi: 10.1007/s11864-019-0613-x. Review.

PMID:
30762130
6.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.

Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.

PMID:
30739911
7.

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup.

Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: Lancet Oncol. 2019 Mar;20(3):e132.

PMID:
30660609
8.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.

Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG.

BMC Cancer. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.

9.

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.

Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farré N, Zwitter M, Lerouge D, Pourel N, Janicot H, Scherpereel A, Tissing-Tan C, Peignaux K, Geets X, Konopa K, Faivre-Finn C.

J Thorac Oncol. 2019 Jan;14(1):63-71. doi: 10.1016/j.jtho.2018.09.027. Epub 2018 Oct 31.

10.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
11.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C.

BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.

12.

Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.

Smeele P, d'Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean D, Blanquart C.

Mol Cancer. 2018 Oct 11;17(1):148. doi: 10.1186/s12943-018-0891-0.

13.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G.

Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258.

PMID:
30060030
14.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800349. doi: 10.1183/13993003.00349-2018. Print 2018 Jul. Review.

PMID:
30054348
15.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

PMID:
29966799
16.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N.

J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.

PMID:
29723687
17.

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study.

Vannimenus C, Bricout H, Le Rouzic O, Mouawad F, Chevalier D, Dansin E, Rotsaert L, Lefebvre G, Cottencin O, Porte H, Scherpereel A, El Fahsi A, Richard F, Rolland B; ALTAK Study Group.

BMC Cancer. 2018 Apr 3;18(1):372. doi: 10.1186/s12885-018-4253-5.

18.

Novel therapies for malignant pleural mesothelioma.

Scherpereel A, Wallyn F, Albelda SM, Munck C.

Lancet Oncol. 2018 Mar;19(3):e161-e172. doi: 10.1016/S1470-2045(18)30100-1. Review.

PMID:
29508763
19.

A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.

Sculier JP, Lafitte JJ, Berghmans T, Meert AP, Scherpereel A, Roelandts M, Van Cutsem O, Colinet B, Bonduelle Y, Giner V, Paesmans M, Leclercq N, Van Houtte P.

Lung Cancer. 2018 Mar;117:32-37. doi: 10.1016/j.lungcan.2017.12.016. Epub 2018 Jan 31.

PMID:
29496253
20.

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC.

Cancer Med. 2018 Apr;7(4):1102-1109. doi: 10.1002/cam4.1378. Epub 2018 Feb 26.

21.

Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.

Olivier C, Grosbois JM, Cortot AB, Peres S, Heron C, Delourme J, Gierczynski M, Hoorelbeke A, Scherpereel A, Le Rouzic O.

BMC Cancer. 2018 Feb 13;18(1):178. doi: 10.1186/s12885-018-4102-6.

22.

[Anti-tumor immunotherapy in malignant pleural mesothelioma].

Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X.

Rev Mal Respir. 2018 Apr;35(4):465-476. doi: 10.1016/j.rmr.2017.07.025. Epub 2018 Feb 4. Review. French.

PMID:
29415822
23.

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2018 Feb;116:62-66. doi: 10.1016/j.lungcan.2017.12.008. Epub 2017 Dec 14.

PMID:
29413052
24.

Immunotherapy in relapsed mesothelioma.

Brosseau S, Dhalluin X, Zalcman G, Scherpereel A.

Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144. No abstract available.

25.

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer.

Berghmans T, Scherpereel A, Meert AP, Giner V, Lecomte J, Lafitte JJ, Leclercq N, Paesmans M, Sculier JP; European Lung Cancer Working Party (ELCWP).

Front Oncol. 2017 Sep 19;7:217. doi: 10.3389/fonc.2017.00217. eCollection 2017.

26.

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ.

PLoS One. 2017 Aug 25;12(8):e0182798. doi: 10.1371/journal.pone.0182798. eCollection 2017.

27.

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.

Calabrò L, Ceresoli GL, D'Incecco A, Scherpereel A, Aerts J, Maio M.

Cytokine Growth Factor Rev. 2017 Aug;36:25-31. doi: 10.1016/j.cytogfr.2017.07.003. Epub 2017 Jul 12. Review.

PMID:
28736182
28.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL.

Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.

PMID:
28729154
29.

The snake raiser lung: An unusual cause of Salmonella enterica subspecies arizonae pneumonia.

Baranzelli A, Loïez C, Bervar JF, Scherpereel A, Wallet F.

Med Mal Infect. 2017 Oct;47(6):424-425. doi: 10.1016/j.medmal.2017.05.001. Epub 2017 Jun 8. No abstract available.

PMID:
28602385
30.

Pembrolizumab-induced pneumonitis.

Leroy V, Templier C, Faivre JB, Scherpereel A, Fournier C, Mortier L, Wemeau-Stervinou L.

ERJ Open Res. 2017 May 2;3(2). pii: 00081-2016. doi: 10.1183/23120541.00081-2016. eCollection 2017 Apr.

31.

PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?

Lantuejoul S, Le Stang N, Damiola F, Scherpereel A, Galateau-Sallé F.

J Thorac Oncol. 2017 May;12(5):778-781. doi: 10.1016/j.jtho.2017.03.018. No abstract available.

32.

Malignant pleural mesothelioma: new treatments, new hopes?

Scherpereel A.

Eur Respir J. 2017 Mar 15;49(3). pii: 1700319. doi: 10.1183/13993003.00319-2017. Print 2017 Mar. No abstract available.

33.

Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment.

Betrouni N, Munck C, Bensoltana W, Baert G, Dewalle-Vignion AS, Scherpereel A, Mordon S.

Photodiagnosis Photodyn Ther. 2017 Jun;18:155-161. doi: 10.1016/j.pdpdt.2017.02.011. Epub 2017 Feb 22.

34.

Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection.

Sanges S, Wallet F, Blondiaux N, Theis D, Vérin I, Vachée A, Dessein R, Faure K, Viget N, Senneville E, Leroy O, Maury F, Just N, Poissy J, Mathieu D, Prévotat A, Chenivesse C, Scherpereel A, Smith G, Lopez B, Rosain J, Frémeaux-Bacchi V, Hachulla E, Hatron PY, Bahuaud M, Batteux F, Launay D, Labalette M, Lefèvre G.

Clin Microbiol Infect. 2017 Aug;23(8):576.e1-576.e5. doi: 10.1016/j.cmi.2017.02.005. Epub 2017 Feb 10.

35.

Prophylactic radiotherapy to prevent procedure-tract metastases.

Zalcman G, Brosseau S, Scherpereel A.

Lancet Oncol. 2016 Oct;17(10):e417. doi: 10.1016/S1470-2045(16)30387-4. No abstract available.

PMID:
27733263
36.

VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study.

Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP; European Lung Cancer Working Party.

ERJ Open Res. 2015 Oct 19;1(2). pii: 00029-2015. eCollection 2015 Oct.

37.

Inequalities in lung cancer: a world of EGFR.

Carbonnaux M, Souquet PJ, Meert AP, Scherpereel A, Peters M, Couraud S.

Eur Respir J. 2016 May;47(5):1502-9. doi: 10.1183/13993003.01157-2015. Epub 2016 Mar 30.

38.

[Asbestos and respiratory diseases].

Scherpereel A.

Presse Med. 2016 Jan;45(1):117-32. doi: 10.1016/j.lpm.2015.12.011. Epub 2016 Jan 26. French.

PMID:
26822071
39.

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT).

Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24.

PMID:
26719230
40.

FDG PET/CT allowing detection and follow-up of tumor cell transplantation.

Jaillard A, Baillet C, Béron A, Tabibzadeh N, Scherpereel A, Frimat M, Perbet R, Gnemmi V, Noël C, Huglo D.

Ann Nucl Med. 2016 Apr;30(3):250-4. doi: 10.1007/s12149-015-1051-x. Epub 2015 Dec 17.

PMID:
26681195
41.

Access to Innovative Drugs in Patients with Metastatic Lung Cancer in French Public Hospitals (the Territoire Study).

Scherpereel A, Fernandes J, Cotté F, Blein C, Debieuvre D, Durand-Zaleski I, Gaudin A, Ozan N, Saitta B, Souquet P, Vainchtock A, Westeel V, Chouaïd C.

Value Health. 2015 Nov;18(7):A341. doi: 10.1016/j.jval.2015.09.145. Epub 2015 Oct 20. No abstract available.

42.

Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.

Yip C, Tacelli N, Remy-Jardin M, Scherpereel A, Cortot A, Lafitte JJ, Wallyn F, Remy J, Bassett P, Siddique M, Cook GJ, Landau DB, Goh V.

J Thorac Imaging. 2015 Sep;30(5):300-7. doi: 10.1097/RTI.0000000000000164.

PMID:
26164165
43.

Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.

Chaouche-Mazouni S, Scherpereel A, Zaamoum R, Mihalache A, Amir ZC, Lebaïli N, Delaire B, Gosset P.

Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.

PMID:
25935651
44.

Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?

Munck C, Mordon SR, Scherpereel A, Porte H, Dhalluin X, Betrouni N.

Ann Thorac Surg. 2015 Jun;99(6):2237-45. doi: 10.1016/j.athoracsur.2014.12.077. Epub 2015 Apr 23. Review.

PMID:
25912746
45.

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party.

Berghmans T, Ameye L, Lafitte JJ, Colinet B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert AP, Paesmans M, Richez M, Scherpereel A, Tulippe C, Willems L, Dernies T, Leclercq N, Sculier JP; European Lung Cancer Working Party.

Front Oncol. 2015 Jan 28;4:386. doi: 10.3389/fonc.2014.00386. eCollection 2014.

46.

The non glycanated endocan polypeptide slows tumor growth by inducing stromal inflammatory reaction.

Yassine H, De Freitas Caires N, Depontieu F, Scherpereel A, Awad A, Tsicopoulos A, Leboeuf C, Janin A, Duez C, Grigoriu B, Lassalle P.

Oncotarget. 2015 Feb 20;6(5):2725-35.

47.

[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates].

Berghmans T, Cortot A, CsToth I, Garcia C, Giner-Marco V, Grigoriu B, Holbrechts S, Lafitte JJ, Meert AP, Moretti L, Paesmans M, Remmelink M, Richez M, Roelandts M, Scherpereel A, Tulippe C, Van Houtte P, Sculier JP; European Lung Cancer Working Party.

Rev Med Brux. 2014 May-Jun;35(3):132-3. French. No abstract available.

PMID:
25102578
48.

Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.

Olivier A, Petyt G, Cortot A, Scherpereel A, Hossein-Foucher C.

Nucl Med Commun. 2014 Sep;35(9):908-15. doi: 10.1097/MNM.0000000000000145.

PMID:
24785008
49.

The European initiative for quality management in lung cancer care.

Blum TG, Rich A, Baldwin D, Beckett P, De Ruysscher D, Faivre-Finn C, Gaga M, Gamarra F, Grigoriu B, Hansen NC, Hubbard R, Huber RM, Jakobsen E, Jovanovic D, Konsoulova A, Kollmeier J, Massard G, McPhelim J, Meert AP, Milroy R, Paesmans M, Peake M, Putora PM, Scherpereel A, Schönfeld N, Sitter H, Skaug K, Spiro S, Strand TE, Taright S, Thomas M, van Schil PE, Vansteenkiste JF, Wiewrodt R, Sculier JP.

Eur Respir J. 2014 May;43(5):1254-77. doi: 10.1183/09031936.00106913. Epub 2014 Mar 23.

50.

[The French mesothelioma network from 1998 to 2013].

Galateau-Sallé F, Gilg Soit Ilg A, Le Stang N, Brochard P, Pairon JC, Astoul P, Frenay C, Blaizot G, Chamming's S, Ducamp S, Rousvoal T, de Quillacq A, Abonnet V, Abdalsamad I, Begueret H, Brambilla E, Capron F, Copin MC, Danel C, de Lajartre AY, Foulet-Roge A, Garbe L, Groussard O, Giusiano S, Hofman V, Lantuejoul S, Piquenot JM, Rouquette I, Sagan C, Thivolet-Bejui F, Vignaud JM, Scherpereel A, Jaurand MC, Jean D, Hainaut P, Chérié-Challine L, Goldberg M, Luce D, Imbernon E.

Ann Pathol. 2014 Feb;34(1):51-63. doi: 10.1016/j.annpat.2014.01.009. Epub 2014 Feb 26. French.

Supplemental Content

Loading ...
Support Center